Dapagliflozin Protects against Cisplatin-Induced Acute Kidney Injury Through Direct Actions on Primary Human Renal Proximal Tubular Epithelial Cells

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/0e2adcbe2b5a46a7f2193e600ba41fe8.pdf
Dapagliflozin Protects against Cisplatin-Induced Acute Kidney Injury Through Direct Actions on Primary Human Renal Proximal Tubular Epithelial Cells

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Iori
Morita
Iori Morita m1705iori@gmail.com Institute of Science Tokyo School of Medicine Tokyo Japan *
Yuta Sekiguchi Dapagliflozin directly protects primary human renal proximal tubular epithelial cells from cisplatin-induced injury by downregulating KIM-1 and PD-L1 expression and mitigating paracrine pro-fibrotic signaling. These effects suppress myofibroblast activation and may prevent the maladaptive transition from AKI to CKD. Our findings reveal a direct tubular mechanism contributing SGLT2 inhibitor-mediated renoprotection, independent of glomerular hemodynamic effects. Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Makiko Mori mmori.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Yuki Nakao 212003ms@tmd.ac.jp Institute of Science Tokyo School of Medicine Tokyo Japan -
Shintaro Mandai smandai.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Hiroaki Kikuchi hkikuchi.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Fumiaki Ando fandoh.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Koichiro Susa ksusa.kid.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Takayasu Mori tmori.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Eisei Sohara esohara.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Shinichi Uchida suchida.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
Yutaro Mori ymori.kid@tmd.ac.jp Institute of Science Tokyo Department of Nephrology Tokyo Japan -
-
-
-